Sumatriptan and Lenvima drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Sumatriptan (sumatriptan succinate) and Lenvima (lenvatinib mesylate). Common drug interactions include atrial fibrillation among females and blood pressure increased among males.

The phase IV clinical study analyzes what interactions people have when they take Sumatriptan and Lenvima. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Sumatriptan?

Sumatriptan has active ingredients of sumatriptan succinate. It is often used in migraine. eHealthMe is studying from 18,159 Sumatriptan users. Check the latest studies of Sumatriptan.

What is Lenvima?

Lenvima has active ingredients of lenvatinib mesylate. eHealthMe is studying from 21,113 Lenvima users. Check the latest studies of Lenvima.

On Jul, 09, 2026

12 people who take Sumatriptan and Lenvima together, and have interactions are studied.

Sumatriptan and Lenvima drug interactions.

What are the common drug interactions of Sumatriptan and Lenvima, by gender? *:

female:

Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Blood pressure increased
Dehydration (dryness resulting from the removal of water)
Diarrhoea
Fatigue (feeling of tiredness)
Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
Hypokalaemia (low potassium)
Hypotension (abnormally low blood pressure)
Lactic acidosis (low ph in body tissues)
Lung infiltration (a substance that normally includes fluid, inflammatory exudates or cells that fill a region of lung)

male:

Blood pressure increased
Aneurysm (enlargement of an artery caused by a weakening of the artery wall)
Diarrhoea
Dysphonia (speech disorder attributable to a disorder of phonation)
Intestinal perforation (complete penetration of the wall of the intestine)
Pneumonia

What are the common drug interactions of Sumatriptan and Lenvima, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Malaise (a feeling of general discomfort or uneasiness)
Intestinal perforation (complete penetration of the wall of the intestine)
Pneumonia

50-59:

Drug ineffective
Eating disorder
Hypersomnia (excessive daytime sleepiness (eds))
Pneumonia
Dyspnoea (difficult or laboured respiration)
Pulmonary embolism (blockage of the main artery of the lung)
Blood pressure increased
Hypertension (high blood pressure)

60+:

Blood pressure increased
Diarrhoea
Lactic acidosis (low ph in body tissues)
Lung infiltration (a substance that normally includes fluid, inflammatory exudates or cells that fill a region of lung)
Malaise (a feeling of general discomfort or uneasiness)
Malnutrition (a condition that results from eating a diet in which certain nutrients are lacking)
Pleural effusion (water on the lungs)
Pulmonary mass
Sepsis (a severe blood infection that can lead to organ failure and death)
Vomiting

What are the existing conditions these people have? *

Renal Cell Carcinoma (a kidney cancer): 7 people, 58.33%
Thyroid Cancer: 3 people, 25.00%
Neoplasm Malignant (cancer tumour): 3 people, 25.00%
Retroperitoneal Neoplasm Metastatic (tumour between peritoneum and the posterior abdominal wall spreads out): 1 person, 8.33%
Ovarian Cancer (cancer of ovary): 1 person, 8.33%
Metastases To Lymph Nodes (cancer spreads to lymph node): 1 person, 8.33%
Metastases To Lung (cancer spreads to lung): 1 person, 8.33%
Metastases To Liver (cancer spreads to liver): 1 person, 8.33%
Gastrointestinal Neoplasm (cancer tumour of digestive tract): 1 person, 8.33%
Endometrial Neoplasm (tumour of uterus wall): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Sumatriptan and Lenvima?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously